Sanofi
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
0.1% vs price
Base Case (Median)
19.2% vs price
Bull Case (75th pct.)
104.9% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $52.91 | -40.2% | High (40%) |
| PE Comparable | $188.35 | 112.8% | Medium (25%) |
| Growth Trajectory DCF | $174.32 | 97.0% | Medium (20%) |
| Graham Number | $105.49 | 19.2% | Medium (40%) |
| EV/EBITDA | $102.06 | 15.3% | Medium (20%) |
| EV/FCF | $250.33 | 182.9% | Medium (20%) |
| Earnings Power Value | $75.21 | -15.0% | Medium (50%) |
Based on 7 out of 8 methods, SNYNF appears undervalued at the current price of $88.50. The base case fair value of $105.49 implies 19.2% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.